Empagliflozin in type 1 diabetes
Chantal Mathieu, Laura Van Den Mooter, Bert EeckhoutEndocrinology, UZ Gasthuisberg, Leuven 3000, BelgiumCorrespondence: Chantal MathieuEndocrinology, UZ Gasthuisberg, Herestraat 49, Leuven 3000, BelgiumEmail chantal.mathieu@uzleuven.beAbstract: There is a clear unmet need in people living with type...
Enregistré dans:
Auteurs principaux: | Mathieu C, Van Den Mooter L, Eeckhout B |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/98d3c9d7fe344aa798dd92c4723adf3c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
par: Simes BC, et autres
Publié: (2019) -
Empagliflozin: a new strategy for nephroprotection in diabetes
par: Anton Ivanovich Korbut, et autres
Publié: (2017) -
Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
par: Ito H, et autres
Publié: (2019) -
Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
par: Ahmadieh H, et autres
Publié: (2017) -
Canagliflozin review – safety and efficacy profile in patients with T2DM
par: Jakher H, et autres
Publié: (2019)